We Think Oxford Nanopore Technologies (LON:ONT) Can Afford To Drive Business Growth
Mar 31
Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedApr 26, 2026
DataAggregated Company Financials
Companies7
- 7D-8.1%
- 3M-28.0%
- 1Y-4.4%
- YTD-6.1%
Over the last 7 days, the Life Sciences industry has dropped 8.1%, driven by Oxford Nanopore Technologies declining 9.2%. On the other hand Diaceutics is actually up 5.8%. However, the industry is down 4.2% over the past year. Looking forward, earnings are forecast to grow by 58% annually.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 26 Apr 2026 | UK£1.4b | UK£318.2m | -UK£167,469,254.00 | n/a | -8.1x | 4.3x |
| Tue, 24 Mar 2026 | UK£1.3b | UK£324.0m | -UK£161,423,254.00 | 8.8x | -8.3x | 4.1x |
| Thu, 19 Feb 2026 | UK£1.5b | UK£304.7m | -UK£159,511,254.00 | 12.6x | -9.7x | 5.1x |
| Sat, 17 Jan 2026 | UK£1.7b | UK£304.6m | -UK£159,441,254.00 | 7.5x | -10.7x | 5.6x |
| Mon, 15 Dec 2025 | UK£1.4b | UK£304.4m | -UK£160,881,254.00 | 6.8x | -8.8x | 4.6x |
| Wed, 12 Nov 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.3x | -9.7x | 5.2x |
| Fri, 10 Oct 2025 | UK£1.7b | UK£304.3m | -UK£163,156,254.00 | 8.4x | -10.2x | 5.5x |
| Sun, 07 Sep 2025 | UK£1.8b | UK£313.5m | -UK£158,190,352.00 | 6.5x | -11.3x | 5.7x |
| Tue, 05 Aug 2025 | UK£2.1b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -13.2x | 7.3x |
| Thu, 03 Jul 2025 | UK£1.6b | UK£291.9m | -UK£160,968,352.00 | 6.9x | -9.7x | 5.4x |
| Sat, 31 May 2025 | UK£1.6b | UK£319.6m | -UK£190,958,890.00 | 5.6x | -8.2x | 4.9x |
| Mon, 28 Apr 2025 | UK£1.6b | UK£313.9m | -UK£192,362,214.35 | 10.9x | -8.4x | 5.1x |
| Wed, 26 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,166,002.35 | 6.1x | -7.9x | 4.7x |
| Fri, 21 Feb 2025 | UK£1.9b | UK£306.4m | -UK£195,112,242.72 | 6.9x | -9.6x | 6.1x |
| Sun, 19 Jan 2025 | UK£2.1b | UK£307.8m | -UK£196,207,193.76 | 7.1x | -10.5x | 6.7x |
| Tue, 17 Dec 2024 | UK£2.1b | UK£306.2m | -UK£195,009,323.04 | 8.1x | -10.9x | 7x |
| Thu, 14 Nov 2024 | UK£2.0b | UK£305.5m | -UK£193,360,229.68 | 10.8x | -10.2x | 6.5x |
| Sat, 12 Oct 2024 | UK£2.0b | UK£304.4m | -UK£192,350,536.90 | 10.6x | -10.4x | 6.6x |
| Mon, 09 Sep 2024 | UK£2.0b | UK£293.4m | -UK£192,317,721.90 | 12.2x | -10.4x | 6.8x |
| Wed, 07 Aug 2024 | UK£1.8b | UK£295.9m | -UK£190,207,202.28 | 12x | -9.7x | 6.2x |
| Fri, 05 Jul 2024 | UK£1.6b | UK£295.7m | -UK£190,052,523.87 | 11.7x | -8.2x | 5.3x |
| Sun, 02 Jun 2024 | UK£1.6b | UK£295.6m | -UK£189,808,553.55 | 11.3x | -8.6x | 5.5x |
| Tue, 30 Apr 2024 | UK£1.5b | UK£292.8m | -UK£188,866,378.07 | 7254.8x | -8x | 5.2x |
| Thu, 28 Mar 2024 | UK£1.8b | UK£295.9m | -UK£213,188,106.13 | 7353.3x | -8.4x | 6.1x |
| Sat, 24 Feb 2024 | UK£1.9b | UK£285.8m | -UK£189,209,049.14 | 6964.3x | -10.3x | 6.8x |
| Mon, 22 Jan 2024 | UK£2.9b | UK£450.2m | -UK£176,590,140.00 | 62.1x | -16.2x | 6.4x |
| Wed, 20 Dec 2023 | UK£3.1b | UK£449.9m | -UK£173,918,274.00 | 52.7x | -17.9x | 6.9x |
| Fri, 17 Nov 2023 | UK£3.0b | UK£455.8m | -UK£168,936,857.00 | 50.3x | -18x | 6.7x |
| Sun, 15 Oct 2023 | UK£2.9b | UK£458.7m | -UK£165,688,739.00 | 51.1x | -17.6x | 6.3x |
| Tue, 12 Sep 2023 | UK£3.1b | UK£440.3m | -UK£166,835,037.00 | 67.5x | -18.6x | 7x |
| Thu, 10 Aug 2023 | UK£3.4b | UK£476.6m | -UK£124,757,538.00 | 70.6x | -27.5x | 7.2x |
| Sat, 08 Jul 2023 | UK£2.9b | UK£476.3m | -UK£124,525,700.00 | 66.1x | -23.4x | 6.1x |
| Mon, 05 Jun 2023 | UK£3.3b | UK£477.0m | -UK£116,998,754.00 | 67.8x | -28.5x | 7x |
| Wed, 03 May 2023 | UK£3.2b | UK£480.2m | -UK£117,304,256.00 | 36.7x | -26.9x | 6.6x |
Price to Earnings Ratio
-26.9x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.9x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 13% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -2.67% | |
| Healthcare | -6.56% | |
| Life Sciences | -8.07% | |
| Clinical Research and Equipment | -8.07% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IXI IXICO | UK£0.07 | -1.8% UK£8.7m | -22.2% | PS2.3x | |
| DXRX Diaceutics | UK£1.74 | 5.8% +UK£8.0m | 46.8% | PS4.3x | |
| OBD Oxford BioDynamics | UK£0.0023 | 2.2% +UK£214.5k | -45.9% | PS9x | |
| PYC Physiomics | UK£0.005 | 3.1% +UK£68.0k | 13.6% | PS2.2x |